The GMEB2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte cell line. This product provides a heterogeneous pool of cells carrying targeted disruptions in the GMEB2 gene, enabling loss-of-function studies without clonal selection. It serves as a versatile research tool for investigating glucocorticoid and TGF-beta signaling in a B-cell context.
Raji cells are a lymphoblastoid cell line established from a Burkitt lymphoma patient, representing mature B lymphocytes with characteristics of the germinal center stage. These cells express surface immunoglobulins and are widely used to study humoral immunity, B-cell malignancies, and apoptosis signaling. Their derivation from an aggressive lymphoma makes them particularly relevant for cancer biology and drug sensitivity screening.
GMEB2 functions as a transcriptional coregulator that fine-tunes gene expression by interacting with the glucocorticoid receptor (GR) and Smad2/3 transcription factors. It participates in the assembly of transcriptional complexes containing PARP-1 and CBP/p300, integrating signals from glucocorticoids and TGF-beta. Upon ligand activation, the GR translocates to the nucleus and recruits GMEB2 to glucocorticoid-responsive gene promoters, while TGF-beta receptor-mediated phosphorylation of Smad2/3 enables their association with GMEB2 at TGF-beta-responsive elements. Through these interactions, GMEB2 modulates the transcription of downstream targets, including members of the Bcl-2 family and caspases, thereby exerting control over apoptosis and cell proliferation.
In Raji B lymphocytes, GMEB2 plays a critical role in mediating glucocorticoid-induced apoptosis and TGF-beta-driven gene regulation. Disruption of GMEB2 in these polyclonal knockout cells abrogates the normal transcriptional responses to glucocorticoids and TGF-beta, leading to altered cell survival and proliferative capacity. This model is particularly informative for dissecting the mechanisms of glucocorticoid resistance and TGF-beta signaling in B-cell lymphoma, offering a platform to explore pathways that govern immune cell fate and oncogenic transformation.
The GMEB2 Knockout Raji Polyclonal Cells are suited for a range of functional assays, including Western blotting and RT-qPCR for protein and mRNA expression analysis, RNA-seq for transcriptome profiling, ChIP-qPCR for assessing GMEB2 occupancy at target promoters, immunofluorescence for subcellular localization, flow cytometry for surface marker and cell cycle analysis, apoptosis assays using Annexin V/PI staining, and co-immunoprecipitation to probe protein?Cprotein interactions. Additionally, reporter assays with GRE-luciferase or TGF-beta-responsive constructs allow quantitative assessment of pathway activity, and drug sensitivity studies enable screening of compounds targeting glucocorticoid or TGF-beta pathways. For further technical information, please contact Ascent Research.
